ELVN

Enliven Therapeutics Inc

Mar 25 • 04:00PM ET

35.53

+4.38 14.06 %

Healthcare • Biotechnology • USA • NASD

Mar 25, 5:30 AMAnalyst price target hike on positive ELVN-001 Phase 1b CML data drives premarket surge.

Peers: REGN VRTX ALNY IONS BMRN INCY NBIX PRTA EXEL ONC

| Held by: VTI IWM VXF IWO IBB SCHA XPH VTWO DFAS IHE

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.86	Insider Own	27.06%	Shs Outstand	59.44M	Perf Week	30.39%
Market Cap	2.12B	Forward P/E	-	EPS next Y	-2.78	Insider Trans	-2.46%	Shs Float	43.62M	Perf Month	25.46%
Enterprise Value	1.66B	PEG	-	EPS next Q	-0.46	Inst Own	82.05%	Short Float	18.83%	Perf Quarter	98.16%
Income	-103.69M	P/S	-	EPS this Y	-14.21%	Inst Trans	-0.52%	Short Ratio	6.87	Perf Half Y	85.15%
Sales	0.00M	P/B	4.60	EPS next Y	-32.94%	ROA	-25.86%	Short Interest	8.22M	Perf YTD	130.71%
Book/sh	7.73	P/C	4.59	EPS next 5Y	-23.50%	ROE	-26.95%	52W High	31.75 11.89%	Perf Year	66.65%
Cash/sh	7.74	P/FCF	-	EPS past 3/5Y	46.65% 33.56%	ROIC	-22.56%	52W Low	13.30 167.14%	Perf 3Y	54.48%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.71% 6.82%	Perf 5Y	3.89%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	2.24%	Oper. Margin	-	ATR (14)	2.18	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	28.66	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	72.28	Recom	1.11
Dividend Gr. 3/5Y	- -	Current Ratio	28.66	EPS Q/Q	-2.58%	SMA20	19.93%	Beta	0.34	Target Price	45.12
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	26.85%	Rel Volume	5.79	Prev Close	31.15
Employees	60	LT Debt/Eq	0.00	Earnings	Mar 03 AMC	SMA200	60.87%	Avg Volume	1.20M	Price	35.53
IPO	Mar 12, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-24.68% -100.00%	Trades		Volume	6,420,712	Change	14.06%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-16-25	Initiated	Goldman	Buy	$37
Dec-13-24	Initiated	BTIG Research	Buy	$42
Sep-09-24	Initiated	H.C. Wainwright	Buy	$37
Jun-11-24	Initiated	Robert W. Baird	Outperform	$32
Apr-09-24	Initiated	Mizuho	Buy	$34
Mar-29-23	Initiated	Jefferies	Buy	$27

Feb-25-26 04:05PM	Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference (PR Newswire)
Jan-08-26 02:16PM	Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars (Benzinga) +50.29%
09:00AM	Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones (PR Newswire)
Jan-07-26 09:00AM	Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development (PR Newswire)
Dec-11-25 04:21PM	Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules (PR Newswire) -6.94% -10.18%
09:00AM	Loading…
09:00AM	Enliven Therapeutics Announces New CEO to Drive Next Phase of Development (PR Newswire)
Dec-03-25 09:55AM	Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade (Zacks)
Nov-17-25 09:55AM	Does Enliven Therapeutics, Inc. (ELVN) Have the Potential to Rally 87.49% as Wall Street Analysts Expect? (Zacks)
Nov-12-25 04:05PM	Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update (PR Newswire)
Sep-12-25 09:55AM	Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know (Zacks)
Sep-09-25 12:00PM	Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-27-25 09:55AM	How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41% (Zacks)
Aug-25-25 06:20PM	Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting (PR Newswire)
Aug-13-25 04:05PM	Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update (PR Newswire) +5.80%
Jul-18-25 09:55AM	Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect? (Zacks)
01:33PM	Loading…
Jun-17-25 01:33PM	Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data (Insider Monkey) -5.59%
Jun-16-25 04:05PM	Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire) +5.39%
Jun-13-25 09:30AM	Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire) +11.44%
06:10AM	Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
06:02AM	Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress (PR Newswire)
May-22-25 04:05PM	Enliven Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
May-17-25 12:40PM	Enliven price target lowered to $27 from $36 at JonesResearch (TipRanks)
May-14-25 04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (PR Newswire) -10.41%
09:56AM	Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress (PR Newswire)
Apr-22-25 02:54PM	Enliven Therapeutics: Awaiting Additional Trial Data (Seeking Alpha) +10.79%
Apr-02-25 04:03PM	Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting (PR Newswire) +5.19%
Mar-13-25 04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (PR Newswire)
Feb-25-25 04:05PM	Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (PR Newswire) -5.71%
Jan-31-25 07:00AM	Biotech walks a 'tightrope' amid unclear funding, regulations (Yahoo Finance Video)
Nov-13-24 04:05PM	Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update (PR Newswire) -5.04%
04:05PM	Loading…
Nov-07-24 04:05PM	Enliven Therapeutics to Present at the Jefferies London Healthcare Conference (PR Newswire)
Oct-18-24 04:38PM	Why this largely unknown company is one analyst's top biotech pick (Yahoo Finance Video)
Oct-04-24 09:00AM	FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket (PR Newswire) +7.92%
Sep-30-24 04:52AM	Enliven Therapeutics ELVN-001 shows promise in Phase I CML trial (Clinical Trials Arena) +5.84%
Sep-28-24 09:35AM	Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Sep-26-24 08:50AM	Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going (Zacks)
Sep-18-24 04:05PM	Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML (GlobeNewswire) +6.02%
Sep-09-24 02:05PM	Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst (Benzinga) +7.28%
Sep-04-24 09:55AM	Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High? (Zacks)
Aug-16-24 09:55AM	Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet (Zacks)
Aug-13-24 04:05PM	Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update (GlobeNewswire)
May-29-24 04:05PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) -8.14% +5.67%
May-20-24 05:06PM	Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing (MT Newswires)
May-14-24 10:54PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:01PM	Enliven Therapeutics Q1 Loss Narrows (MT Newswires)
04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (GlobeNewswire)
Apr-19-24 03:03PM	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-11-24 03:44PM	Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program (Benzinga) +20.18%
07:55AM	Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Apr-09-24 04:05PM	Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024 (GlobeNewswire) -5.58% +7.45%
Mar-23-24 01:51AM	Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares (GuruFocus.com)
Mar-19-24 08:30AM	Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates (GlobeNewswire) +38.77%
Mar-14-24 09:53PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -5.95%
04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-27-24 04:05PM	Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Jan-03-24 09:01AM	Enliven Therapeutics Inc CFO Benjamin Hohl Sells 11,870 Shares (GuruFocus.com)
Nov-09-23 04:05PM	Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) -7.97%
Aug-17-23 06:40AM	7 A-Rated Biotech Stocks for Your August Buy List (InvestorPlace) +6.00%
Aug-10-23 04:05PM	Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-31-23 04:55PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) +8.85%
May-11-23 04:05PM	Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Mar-24-23 06:30AM	7 Biotech Stocks Sitting in the Sweet Spot (InvestorPlace)

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Collins Helen Louise	Officer	Mar 25 '26	Proposed Sale	31.15	45,000	1,401,750		Mar 25 04:29 PM
Patel Anish	Officer	Mar 24 '26	Proposed Sale	30.81	100,000	3,081,000		Mar 24 04:26 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 17 '26	Option Exercise	2.48	5,000	12,400	30,000	Mar 19 05:50 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 17 '26	Sale	27.76	5,000	138,800	25,000	Mar 19 05:50 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 09 '26	Option Exercise	2.48	29,871	74,080	54,871	Mar 11 05:32 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 10 '26	Option Exercise	2.48	10,129	25,120	35,129	Mar 11 05:32 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 09 '26	Sale	30.02	29,871	896,811	25,000	Mar 11 05:32 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 10 '26	Sale	30.19	10,129	305,827	25,000	Mar 11 05:32 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 06 '26	Sale	29.58	10,000	295,839	51,000	Mar 10 06:15 PM
Collins Helen Louise	Officer	Mar 09 '26	Proposed Sale	29.44	45,000	1,324,800		Mar 09 04:12 PM
Hohl Benjamin	Officer	Mar 06 '26	Proposed Sale	29.29	10,000	292,900		Mar 06 04:06 PM
Heyman Richard A.	Director	Feb 17 '26	Sale	26.18	1,230	32,196	22,647	Feb 19 06:38 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Feb 17 '26	Option Exercise	2.48	45,000	111,600	70,000	Feb 19 06:36 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Feb 17 '26	Sale	26.17	45,000	1,177,862	25,000	Feb 19 06:36 PM
Lyssikatos Joseph P	Officer	Feb 18 '26	Proposed Sale	26.13	75,000	1,959,750		Feb 18 04:25 PM
Kintz Samuel	Officer	Feb 17 '26	Proposed Sale	26.72	75,000	2,004,000		Feb 17 04:50 PM
Heyman Richard A.	Director	Feb 17 '26	Proposed Sale	26.72	1,230	32,866		Feb 17 04:44 PM
Collins Helen Louise	Officer	Feb 17 '26	Proposed Sale	26.72	45,000	1,202,400		Feb 17 04:40 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Feb 06 '26	Sale	29.04	5,000	145,219	740,188	Feb 10 06:12 PM
ANDREW PHILLIPS	Former Director	Feb 02 '26	Proposed Sale	28.00	21,844	611,719		Feb 02 05:38 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jan 20 '26	Sale	26.75	20,000	535,099	745,188	Jan 22 05:34 PM
Heyman Richard A.	Director	Jan 20 '26	Sale	26.75	1,230	32,902	23,877	Jan 22 05:33 PM
Heyman Richard A.	Director	Jan 20 '26	Proposed Sale	26.71	1,230	32,853		Jan 20 04:55 PM
Patel Anish	CHIEF OPERATING OFFICER	Jan 09 '26	Sale	27.99	48,300	1,351,762	215,011	Jan 13 05:54 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jan 09 '26	Sale	27.22	91,198	2,482,578	765,188	Jan 12 05:12 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jan 08 '26	Sale	24.05	41,302	993,436	856,386	Jan 12 05:12 PM
Heyman Richard A.	Director	Jan 08 '26	Sale	25.03	9,635	241,156	25,545	Jan 12 05:11 PM
Heyman Richard A.	Director	Jan 09 '26	Sale	25.00	4,285	107,125	25,107	Jan 12 05:11 PM
Lyssikatos Joseph P	Officer	Jan 09 '26	Proposed Sale	23.25	75,000	1,743,750		Jan 09 04:50 PM
Kintz Samuel	Officer	Jan 09 '26	Proposed Sale	23.25	75,000	1,743,750		Jan 09 04:49 PM
Patel Anish	Officer	Jan 09 '26	Proposed Sale	23.25	48,300	1,122,975		Jan 09 04:18 PM
Kintz Samuel	Officer	Jan 08 '26	Proposed Sale	15.47	82,500	1,276,275		Jan 08 04:42 PM
Lyssikatos Joseph P	Officer	Jan 08 '26	Proposed Sale	15.47	82,500	1,276,275		Jan 08 04:26 PM
Heyman Richard A.	Director	Jan 08 '26	Proposed Sale	15.47	1,620	25,061		Jan 08 04:26 PM
Heyman Richard A.	Director	Jan 08 '26	Proposed Sale	15.47	12,300	190,281		Jan 08 04:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 22 '25	Option Exercise	2.48	13,000	32,240	36,000	Dec 23 06:47 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Dec 19 '25	Sale	16.84	5,000	84,206	897,688	Dec 23 06:45 PM
Kunkel Lori Anne	Director	Dec 17 '25	Option Exercise	1.12	15,958	17,873	30,712	Dec 19 05:58 PM
Lyssikatos Joseph P	Officer	Dec 19 '25	Proposed Sale	16.68	5,000	83,400		Dec 19 04:32 PM
Kintz Samuel	Officer	Dec 17 '25	Proposed Sale	16.91	5,000	84,550		Dec 17 04:23 PM
Patel Anish	CHIEF OPERATING OFFICER	Dec 08 '25	Sale	21.02	6,663	140,073	263,311	Dec 10 05:13 PM
Patel Anish	Officer	Dec 08 '25	Proposed Sale	21.81	6,663	145,320		Dec 08 04:18 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Nov 19 '25	Sale	22.33	12,500	279,155	902,688	Nov 21 05:28 PM
Kintz Samuel	PRESIDENT AND CEO	Nov 17 '25	Sale	21.82	12,500	272,739	890,392	Nov 19 06:45 PM
Lyssikatos Joseph P	Officer	Nov 19 '25	Proposed Sale	22.59	12,500	282,375		Nov 19 04:05 PM
Kintz Samuel	Officer	Nov 17 '25	Proposed Sale	22.07	12,500	275,875		Nov 17 04:16 PM
Patel Anish	CHIEF OPERATING OFFICER	Nov 07 '25	Sale	17.40	6,667	116,034	269,974	Nov 12 05:34 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 20 '25	Sale	22.08	12,500	276,025	915,188	Oct 22 07:20 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 17 '25	Sale	21.33	12,500	266,654	902,892	Oct 21 06:13 PM
Lyssikatos Joseph P	Officer	Oct 20 '25	Proposed Sale	21.41	12,500	267,625		Oct 20 04:10 PM
Kintz Samuel	Officer	Oct 17 '25	Proposed Sale	21.75	12,500	271,875		Oct 17 04:16 PM
Patel Anish	CHIEF OPERATING OFFICER	Oct 07 '25	Sale	20.10	6,667	133,993	276,641	Oct 09 05:21 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 29 '25	Option Exercise	2.48	3,250	8,060	26,250	Oct 01 04:46 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 29 '25	Sale	20.40	3,250	66,291	23,000	Oct 01 04:46 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Sep 26 '25	Sale	20.25	4,000	81,005	927,688	Sep 30 05:53 PM
Kintz Samuel	PRESIDENT AND CEO	Sep 26 '25	Sale	20.06	3,700	74,228	915,392	Sep 30 05:51 PM
Hohl Benjamin	Officer	Sep 29 '25	Proposed Sale	20.01	4,500	90,045		Sep 29 05:19 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Sep 23 '25	Sale	20.03	1,500	30,045	931,688	Sep 25 07:44 PM
Kintz Samuel	PRESIDENT AND CEO	Sep 23 '25	Sale	20.03	2,800	56,084	919,092	Sep 25 07:42 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Sep 19 '25	Sale	19.39	7,000	135,697	933,188	Sep 23 05:14 PM
Kintz Samuel	PRESIDENT AND CEO	Sep 17 '25	Sale	19.09	5,000	95,473	922,892	Sep 19 07:12 PM
Kintz Samuel	PRESIDENT AND CEO	Sep 19 '25	Sale	20.25	1,000	20,250	921,892	Sep 19 07:12 PM
Lyssikatos Joseph P	Officer	Sep 19 '25	Proposed Sale	19.93	12,500	249,125		Sep 19 05:32 PM
Kintz Samuel	Officer	Sep 17 '25	Proposed Sale	18.43	12,500	230,375		Sep 17 04:08 PM
Patel Anish	CHIEF OPERATING OFFICER	Sep 08 '25	Sale	20.24	6,667	134,957	283,308	Sep 10 08:12 PM
Patel Anish	Officer	Sep 08 '25	Proposed Sale	20.15	20,001	403,020		Sep 08 04:30 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Aug 27 '25	Option Exercise	2.48	3,250	8,060	26,250	Aug 29 05:03 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Aug 27 '25	Sale	20.63	3,250	67,039	23,000	Aug 29 05:03 PM
Hohl Benjamin	Officer	Aug 27 '25	Proposed Sale	20.32	5,250	106,680		Aug 27 04:44 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Aug 21 '25	Sale	20.01	7,500	150,099	940,188	Aug 21 06:46 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Aug 19 '25	Sale	19.62	5,000	98,118	947,688	Aug 21 06:46 PM
Kintz Samuel	PRESIDENT AND CEO	Aug 18 '25	Sale	20.02	10,393	208,106	929,999	Aug 20 04:36 PM
Kintz Samuel	PRESIDENT AND CEO	Aug 19 '25	Sale	20.00	590	11,800	929,409	Aug 20 04:36 PM
Lyssikatos Joseph P	Officer	Aug 19 '25	Proposed Sale	19.75	12,500	246,875		Aug 19 04:24 PM
Kintz Samuel	Officer	Aug 18 '25	Proposed Sale	20.22	12,500	252,750		Aug 18 04:21 PM
Patel Anish	CHIEF OPERATING OFFICER	Aug 07 '25	Sale	18.24	6,667	121,616	289,975	Aug 11 06:51 PM
Patel Anish	Officer	Aug 07 '25	Proposed Sale	18.84	6,667	125,606		Aug 07 04:19 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 28 '25	Option Exercise	2.48	3,250	8,060	26,250	Jul 30 05:57 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 28 '25	Sale	20.46	3,250	66,504	23,000	Jul 30 05:57 PM
Hohl Benjamin	Officer	Jul 28 '25	Proposed Sale	21.20	4,250	90,100		Jul 28 04:09 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jul 21 '25	Sale	22.29	12,500	278,646	952,688	Jul 23 06:52 PM
Kintz Samuel	PRESIDENT AND CEO	Jul 17 '25	Sale	22.52	12,500	281,518	940,392	Jul 21 07:21 PM
Lyssikatos Joseph P	Officer	Jul 21 '25	Proposed Sale	22.66	12,500	283,250		Jul 21 04:10 PM
Kintz Samuel	Officer	Jul 17 '25	Proposed Sale	21.46	12,500	268,250		Jul 17 04:13 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 10 '25	Option Exercise	2.48	1,000	2,480	24,000	Jul 14 05:07 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 10 '25	Sale	22.66	1,000	22,655	23,000	Jul 14 05:07 PM
Patel Anish	CHIEF OPERATING OFFICER	Jul 07 '25	Sale	19.79	6,667	131,951	296,642	Jul 09 07:29 PM
Patel Anish	Officer	Jul 07 '25	Proposed Sale	20.73	6,667	138,207		Jul 07 04:15 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 27 '25	Option Exercise	2.48	3,250	8,060	26,250	Jul 01 04:42 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 27 '25	Sale	20.91	3,250	67,956	23,000	Jul 01 04:42 PM
Hohl Benjamin	Officer	Jun 27 '25	Proposed Sale	21.52	4,250	91,460		Jun 27 04:01 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jun 20 '25	Sale	21.40	12,500	267,458	965,188	Jun 24 05:36 PM
Lyssikatos Joseph P	Officer	Jun 20 '25	Proposed Sale	21.57	12,500	269,625		Jun 20 04:02 PM
Kintz Samuel	PRESIDENT AND CEO	Jun 17 '25	Sale	22.18	12,500	277,292	952,892	Jun 18 06:22 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 13 '25	Option Exercise	2.48	3,000	7,440	26,000	Jun 17 04:24 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 13 '25	Sale	22.55	3,000	67,655	23,000	Jun 17 04:24 PM
Kintz Samuel	Officer	Jun 17 '25	Proposed Sale	23.09	12,500	288,625		Jun 17 04:15 PM
Hohl Benjamin	Officer	Jun 13 '25	Proposed Sale	19.99	3,000	59,980		Jun 13 04:08 PM
Patel Anish	CHIEF OPERATING OFFICER	Jun 09 '25	Sale	20.34	6,667	135,574	303,309	Jun 11 06:25 PM
Patel Anish	Officer	Jun 09 '25	Proposed Sale	20.74	6,667	138,274		Jun 09 04:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELVN

Enliven Therapeutics Inc

Upgrade your FINVIZ experience